Montelukast Sodium Market Analysis

Montelukast Sodium Market Analysis

Based on product type, the market is divided into montelukast sodium amorphous and montelukast sodium crystalline. The montelukast sodium amorphous segment accounted for USD 387.6 million in 2023.
 

• Amorphous forms of drugs often exhibit higher solubility than their crystalline counterparts. This increased solubility can lead to faster dissolution and potentially improved bioavailability, the drug can be absorbed more readily into the bloodstream.
   
• This forms may have better stability under certain conditions such as in the presence of moisture or at higher temperatures, compared to crystalline forms. This improved stability can contribute to longer shelf life and better storage characteristics.
   
• Further, amorphous forms may provide greater flexibility in dosing options due to their enhanced solubility and potentially improved bioavailability. This could allow for the development of alternative dosage forms or strengths to better meet patient needs. Thus, driving the growth of the market.
   

Based on dosage form, the montelukast sodium market is divided into tablets and oral solutions. The tablets segment is estimated to account for USD 985.4 million by the end of 2032.
 

• Tablets are easy to administer and convenient for patients to take, as they can be swallowed whole with water or broken into smaller pieces if necessary.
   
• Montelukast sodium tablets offer accurate dosing and extended stability, ensuring patients receive consistent medication levels and longer-lasting efficacy compared to liquid or suspension formulations.
   
• Further, tablet formulations of montelukast sodium are often cost-effective compared to other dosage forms, making them accessible to a wider range of patients. Thus, propelling the growth of the market.
   

Based on application, the montelukast sodium market is bifurcated into asthma, allergic rhinitis, urticaria, and other applications. The asthma segment accounted for USD 262.9 million in 2023.
 

• Montelukast sodium acts as a leukotriene receptor antagonist, helping to reduce inflammation in the airways. By blocking the action of leukotrienes, it helps to decrease airway inflammation, a key component of asthma.
   
• It can be used as a preventive treatment for asthma particularly in individuals who have persistent asthma symptoms despite using other medications such as inhaled corticosteroids. It can help reduce the frequency and severity of asthma attacks, improving overall asthma control.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on distribution channel, the montelukast sodium market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a market size of USD 277.7 million in the year 2023.
 

• Hospital pharmacies manage formularies, a lists of medications approved for use within the institution. By including montelukast sodium on the formulary, hospitals can ensure consistent availability of the medication for patients who require it.
   
• Hospital pharmacists have specialized knowledge and expertise in medication management including dosing, drug interactions, and adverse effects. They can ensure appropriate prescribing and monitoring of montelukast sodium for patients with asthma or other respiratory conditions.
   
• Therefore, hospital pharmacists also play a key role in patient education and counseling regarding medication use, including montelukast sodium. They can provide information about proper administration, potential side effects, and the importance of adherence to therapy. Thus, such factors are expected to escalate the growth of the market.
   

The U.S. montelukast sodium market is anticipated to grow at CAGR of 11.1% during the analysis timeframe.
 

• The U.S. has a highly developed healthcare infrastructure with advanced medical facilities and a robust pharmaceutical industry. This infrastructure facilitates the production, distribution, and access to montelukast sodium for patients across the country.
   
• The country has a significant prevalence of asthma. For instance, according to the Asthma and Allergy Foundation of America, in 2021 reported that 38.7% of children aged 18 and younger experienced one or more asthma attacks. Among children under the age of 5 with asthma, approximately 63.1% encountered such attacks during the same period. Additionally, 39.6% of adults aged 18 and older with asthma also reported experiencing one or more asthma attacks in the year.
   

The UK is anticipated to witness robust growth in the global montelukast sodium market.
 

• The UK's Medicines and Healthcare products Regulatory Agency (MHRA) upholds rigorous standards for the approval and regulation of pharmaceutical products, including montelukast sodium. This ensures the safety, efficacy, and quality of medications available in the UK market.
   
• The country is home to a wealth of clinical expertise in respiratory medicine, with skilled healthcare professionals specializing in conditions such as asthma and allergic rhinitis. This expertise ensures that montelukast sodium is prescribed and managed appropriately for patients.
   

Japan montelukast sodium market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan's highly advanced healthcare system coupled with universal health coverage, ensures access to medical services for its entire population including affordable medications like montelukast sodium. The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan upholds rigorous standards for approving and monitoring pharmaceutical products, ensuring their safety and efficacy.
   

The montelukast sodium market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia's significant healthcare infrastructure investment, evidenced by the establishment of hospitals, clinics, and specialized centers, widens access to medical services, including respiratory diseases testing, which is estimated to reach USD 26 billion by 2032, and treatment, in addition to medications such as montelukast sodium.
   
• There is a growing awareness of respiratory diseases such as asthma and allergic rhinitis in Saudi Arabia. This increased awareness encourages individuals to seek medical treatment, leading to higher demand for medications such as montelukast sodium.